Solid Biosciences Inc. SLDB
Solid Biosciences Inc. (Nasdaq: SLDB) is a rare genetic drug developer. Its lead program, SGT-003, is in Phase 3 for Duchenne muscular dystrophy. Its next catalyst on record is SGT-003: Type C meeting with FDA to discuss potential accelerated approval pathway and preliminary INSPIRE DUCHENNE data package (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SGT-003 — Type C meeting with FDA to discuss potential accelerated approval pathway and preliminary INSPIRE DUCHENNE data package (Q4 2026). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SGT-003 | Duchenne muscular dystrophy | gene therapy | Phase 3 |
| SGT-212 | Friedreich's ataxia | gene therapy | Phase 1 |
| SGT-501 | catecholaminergic polymorphic ventricular tachycardia (CPVT) | gene therapy | Phase 1 |
| SGT-601 | TNNT2-mediated dilated cardiomyopathy | gene therapy | Pre-clinical |
| POLARIS-101 / AAV-SLB101 capsid | platform technology (myotropic capsid) | gene therapy | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.